S. A. Aziz, S. Pervez, S. Khan, N. Kayani, R. et al., Epidermal growth factor receptor (EGFR) as a prognostic marker: An immunohistochemical study on 315 consecutive breast carcinoma patients, J. Pak. Med. Assoc, vol.52, pp.104-114, 2002.

A. Baruch, M. Hartmann, S. Zrihan-licht, S. Green-stein, M. Burstein et al., Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function, Int. J. Cancer, vol.29, pp.741-749, 1997.

J. Y. Chang, W. Xia, R. Shao, F. Sorgi, G. N. Hortobagyi et al., The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer, Oncogene, vol.14, pp.561-568, 1997.

P. W. Cheng, Receptor ligand-facilitated gene transfer: Enhancement of liposome-mediated gene transfer and expression by transferrin, Hum. Gene Ther, vol.7, pp.275-282, 1996.

K. L. Cheung, C. R. Graves, R. , and J. F. , Tumour marker measurements in the diagnosis and monitoring of breast cancer, Cancer Treat. Rev, vol.26, pp.91-102, 2000.

P. Ciborowski, F. , and O. J. , Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: Potential role in metastasis, Clin. Exp. Metastasis, vol.19, pp.339-345, 2002.

H. F. Clark, A. L. Gurney, E. Abaya, K. Baker, D. Baldwin et al., The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: A bioinformatics assessment, Genome Res, vol.13, pp.2265-2270, 2003.

J. W. Clark, L. Snell, R. P. Shiu, F. W. Orr, N. Maitre et al., The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis, Br. J. Cancer, vol.81, pp.1002-1008, 1999.

T. L. Colpitts, P. Billing, E. Granados, M. Hayden, S. Hodges et al., Identification and immunohistochemical characterization of a mucin-like glycoprotein expressed in early stage breast carcinoma, Tumour Biol, vol.23, pp.263-278, 2002.

G. U. Dachs, G. J. Dougherty, I. J. Stratford, C. , and D. J. , Targeting gene therapy to cancer: A review, Oncol. Res, vol.9, pp.313-325, 1997.

O. D. Ermolaeva, S. , and E. D. , Subtractive hybridization, a technique for extraction of DNA sequences distinguishing two closely related genomes: critical analysis, Genet. Anal, vol.13, pp.49-58, 1996.

S. B. Fox, R. D. Leek, K. Smith, J. Hollyer, M. Greenall et al., Tumor angiogenesis in node-negative breast carcinomas-Relationship with epidermal growth factor receptor, estrogen receptor, and survival, Breast Cancer Res. Treat, vol.29, pp.109-116, 1994.

A. E. Frankel, Immunotoxin therapy of cancer, Oncology, vol.7, pp.69-86, 1993.

W. T. Godbey, A. , and A. , Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery, Gene Ther, vol.10, pp.1519-1527, 2003.

D. E. Haagensen, M. , and G. , Biochemistry and immunohistochemistry of fluid proteins of the breast in gross cystic disease, Diseases of the Breast. C.D. Haagensen, pp.474-500, 1986.

D. F. Hayes, C. Isaacs, S. , and V. , Prognostic factors in breast cancer: Current and new predictors of metastasis, J. Mammary Gland Biol. Neoplasia, vol.6, pp.375-392, 2001.

R. Hilf, M. L. Feldstein, S. L. Gibson, S. , and E. D. , The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer, Cancer, vol.45, 1980.

R. L. Houghton, D. C. Dillon, D. A. Molesh, B. K. Zehentner, J. Xu et al., Transcriptional complementarity in breast cancer: Application to detection of circulating tumor cells, Mol. Diagn, vol.6, pp.79-91, 2001.

L. G. Hudson, A. P. Ertl, G. , and G. N. , Structure and inducible regulation of the human c-erb B2/neu promoter, J. Biol. Chem, vol.265, pp.4389-4393, 1990.

H. C. Hurst, Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment, Breast Cancer Res, vol.3, pp.395-398, 2001.

N. E. Hynes, S. , and D. F. , The biology of erbB-2/ neu/HER-2 and its role in cancer, Biochim. Biophys. Acta, vol.1198, pp.165-184, 1994.

J. N. Ingle, V. J. Suman, C. G. Kardinal, J. E. Krook, J. A. Mail-liard et al., A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma, Cancer, vol.85, pp.1284-1292, 1999.

J. G. Klijn, P. M. Berns, P. I. Schmitz, F. , and J. A. , The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients, Endocr. Rev, vol.13, pp.3-17, 1992.

T. Koga, Y. Horio, T. Mitsudomi, T. Takahashi, Y. et al., Identification of MGB1 as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data, J. Mol. Diagn, vol.6, pp.90-95, 2004.

C. H. Lee, M. Hsiao, Y. L. Tseng, C. , and F. H. , Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with the anti-HER-2 antibody, J. Biomed. Sci, vol.10, pp.337-344, 2003.

E. Leygue, L. Snell, H. Dotzlaw, K. Hole, S. Troup et al., Mammaglobin, a potential marker of breast cancer nodal metastasis, J. Pathol, vol.189, pp.28-33, 1999.

X. Li, W. Gu, S. Mohan, B. , and D. J. , DNA microarrays: Their use and misuse, Microcirculation, vol.9, pp.13-22, 2002.

F. Mannello, G. , and G. , Prostate-specific antigen (PSA/hK3): A further player in the field of breast cancer diagnostics?, Breast Cancer Res, vol.3, pp.238-243, 2001.

J. D. Marth, V. , and A. , O-Glycans, pp.537-549, 1999.

B. H. Mason, I. M. Holdaway, P. R. Mullins, L. H. Yee, K. et al., Progesterone and estrogen receptors as prognostic variables in breast cancer, Cancer Res, vol.43, pp.2985-2990, 1983.

A. Meenakshi, R. S. Kumar, K. , and N. S. , ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients, J. Immunoassay Immunochem, vol.23, pp.293-305, 2002.

R. J. Miksicek, Y. Myal, P. H. Watson, C. Walker, L. C. Mur-phy et al., Identification of a novel breastand salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium, Cancer Res, vol.62, pp.2736-2740, 2002.

L. C. Murphy, M. Lee-wing, G. J. Goldenberg, and R. P. Shiu, Expression of the gene encoding a prolactin-inducible protein by human breast cancers in vivo: Correlation with steroid receptor status, Cancer Res, vol.47, pp.4160-4164, 1987.

Y. Myal, D. B. Robinson, B. Iwasiow, D. Tsuyuki, P. Wong et al., The prolactin-inducible protein (PIP/GCDFP-15) gene: Cloning, structure and regulation, Mol. Cell. Endocrinol, vol.80, pp.165-175, 1991.

M. Nacht, A. T. Ferguson, W. Zhang, J. M. Petroziello, B. P. Cook et al., Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer, Cancer Res, vol.59, pp.5464-5470, 1999.

S. Nicholson, C. Wright, J. R. Sainsbury, P. Halcrow, P. Kelly et al., Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure, J. Steroid Biochem. Mol. Biol, vol.37, pp.811-814, 1990.

S. Paik, P. , and C. , HER-2 and choice of adjuvant chemotherapy in breast cancer, Semin. Oncol, vol.28, pp.332-335, 2001.

H. S. Pandha, L. A. Martin, A. Rigg, H. C. Hurst, G. W. Stamp et al., Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression, J. Clin. Oncol, vol.17, pp.2180-2189, 1999.

M. D. Pegram, G. Pauletti, S. , and D. J. , , 1998.

, HER-2/neu as a predictive marker of response to breast cancer therapy, Breast Cancer Res. Treat, vol.52, pp.65-77

V. Punj, J. M. Graves, M. , and R. R. , Effect of vitamin D analog (1alpha hydroxy D5) immunoconjugated to Her-2 antibody on breast cancer, Int. J. Cancer, vol.108, pp.922-999, 2004.

C. Quan, L. U. , and S. J. , Identification of genes preferentially expressed in mammary epithelial cells of Copenhagen rat using subtractive hybridization and microarrays, Carcinogenesis, vol.24, pp.1593-1599, 2003.

J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark et al., The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy, Oncologist, vol.8, pp.307-325, 2003.

L. L. Shek, G. , and W. , Model for breast cancer survival: Relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis, Cancer Res, vol.48, pp.5565-5569, 1988.

R. P. Shiu, I. , and B. M. , Prolactin-inducible proteins in human breast cancer cells, J. Biol. Chem, vol.260, pp.11307-11313, 1985.

G. Spizzo, G. Gastl, D. Wolf, E. Gunsilius, M. Steurer et al., Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival, Br. J. Cancer, vol.88, pp.574-578, 2003.

V. Stearns, H. Yamauchi, H. , and D. F. , Circulating tumor markers in breast cancer: accepted utilities and novel prospects, Breast Cancer Res. Treat, vol.52, pp.239-259, 1998.

B. Suchy, F. Austrup, G. Driesel, C. Eder, I. Kusiak et al., Detection of mammaglobin expressing cells in blood of breast cancer patients, Cancer Lett, vol.158, pp.171-178, 2000.

J. Taylor-papadimitriou, J. Burchell, D. W. Miles, D. , and M. , MUC1 and cancer, Biochim. Biophys. Acta, vol.1455, pp.301-313, 1999.

V. E. Velculescu, L. Zhang, B. Vogelstein, K. , and K. W. , Serial analysis of gene expression, Science, vol.270, pp.484-487, 1995.

S. Von-mensdorff-pouilly, F. G. Snijdewint, A. A. Ver-straeten, R. H. Verheijen, K. et al., Human MUC1 mucin: A multifaceted glycoprotein, Int. J. Biol. Markers, vol.15, pp.343-356, 2000.

M. A. Watson, F. , and T. P. , Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer, Cancer Res, vol.56, pp.860-865, 1996.

B. Weigelt, P. Verduijn, A. J. Bosma, E. J. Rutgers, H. L. Pe-terse et al., Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers, Br. J. Cancer, vol.90, pp.1531-1537, 2004.

D. A. Wilcox, J. C. Olsen, L. Ishizawa, M. Griffith, and G. C. White, Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirustransduced human hematopoietic cells, Proc. Natl. Acad. Sci. USA, vol.96, pp.9654-9659, 1999.

M. Yoshida, O. Abe, J. Uchino, K. Kikuchi, R. Abe et al., Efficacy of post-operative adjuvant therapy for stage IIIa breast cancer: Futraful vs futrafultamoxifen for ER-positive patients and futraful vs futrafuladriamycin for ERnegative breast cancer, Breast Cancer, vol.4, pp.103-113, 1997.

O. Zach, H. Kasparu, O. Krieger, W. Hehenwarter, M. Girschikofsky et al., Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA, J. Clin. Oncol, vol.17, pp.2015-2019, 1999.

X. Y. Zhao, H. , and M. C. , Negative autoregulation of the neu gene is mediated by a novel enhancer, Mol. Cell. Biol, vol.12, pp.2739-2748, 1992.

K. Zhu, L. J. Bernard, R. S. Levine, W. , and S. M. , Estrogen receptor status of breast cancer: A marker of different stages of tumor or different entities of the disease?, Med. Hypotheses, vol.49, pp.69-75, 1997.

R. L. Zimmerman, F. Fogt, G. , and S. , Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions, Cancer, vol.90, pp.230-234, 2000.